These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 21395034)

  • 1. [Antiviral therapy in a patient with chronic hepatitis C, metabolic syndrome and interferon-induced depression].
    Baĭzhanova ZhZh; Ignatova TM; Kinkul'kina MA
    Klin Med (Mosk); 2010; 88(6):65-7. PubMed ID: 21395034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-α induced lupus in a patient with chronic hepatitis C virus.
    Rizvi R; Hojjati M
    J Clin Rheumatol; 2011 Apr; 17(3):152-3. PubMed ID: 21441813
    [No Abstract]   [Full Text] [Related]  

  • 3. [Combination therapy for chronic viral hepatitis C].
    Zeuzem S
    Dtsch Med Wochenschr; 2003 Feb; 128(8):370-4. PubMed ID: 12594622
    [No Abstract]   [Full Text] [Related]  

  • 4. Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C.
    Yang WS; Chu PL; Liu CH; Chung GB; Wu KD
    J Clin Gastroenterol; 2008 Jan; 42(1):112-3. PubMed ID: 18097301
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.
    Schaefer M; Hinzpeter A; Mohmand A; Janssen G; Pich M; Schwaiger M; Sarkar R; Friebe A; Heinz A; Kluschke M; Ziemer M; Gutsche J; Weich V; Halangk J; Berg T
    Hepatology; 2007 Oct; 46(4):991-8. PubMed ID: 17668880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Rogers CJ; Romagosa R; Vincek V
    J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy.
    Gordon A; Menahem S; Mitchell J; Jenkins P; Dowling J; Roberts SK
    Nephrol Dial Transplant; 2004 Aug; 19(8):2155. PubMed ID: 15252182
    [No Abstract]   [Full Text] [Related]  

  • 8. Peginterferon and ribavirin for chronic hepatitis C.
    Hoofnagle JH; Seeff LB
    N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
    [No Abstract]   [Full Text] [Related]  

  • 9. [Type 1 diabetes developing during alpha-interferon therapy: report of two cases].
    Vinagre I; Rigla M; Torras X; Enríquez J; Corcoy R
    Endocrinol Nutr; 2010 Oct; 57(8):393-5. PubMed ID: 20462813
    [No Abstract]   [Full Text] [Related]  

  • 10. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
    Demirturk N; Aykin N; Demirdal T; Cevik F
    Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
    [No Abstract]   [Full Text] [Related]  

  • 11. Interferon for hepatitis C patients with psychiatric disorders.
    Asnis GM; De La Garza R; Rego SA; Henderson MA; Reinus JF
    Am J Psychiatry; 2004 Dec; 161(12):2332; author reply 2332-4. PubMed ID: 15569920
    [No Abstract]   [Full Text] [Related]  

  • 12. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
    Lopukhova NL
    Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
    [No Abstract]   [Full Text] [Related]  

  • 13. Interferon for hepatitis C patients with psychiatric disorders.
    Wilson MS
    Am J Psychiatry; 2004 Dec; 161(12):2332; author reply 2332-4. PubMed ID: 15569921
    [No Abstract]   [Full Text] [Related]  

  • 14. [Has hepatitis C become curable by a new pegylated interferon?].
    Trépo C; Merle P
    Presse Med; 2001 May; 30(18):905-8. PubMed ID: 11413851
    [No Abstract]   [Full Text] [Related]  

  • 15. [Thrombocytopenia in patients with chronic hepatitis C].
    Bakulin IG; Sharabanov AS; Moliarenko EV; Iakovleva EV
    Eksp Klin Gastroenterol; 2010; (5):52-8, 60; quiz 59, 122. PubMed ID: 20731135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A levitating tattoo in a hepatitis C patient on treatment.
    Atluri D; Iduru S; Veluru C; Mullen K
    Liver Int; 2010 Apr; 30(4):583-4. PubMed ID: 20015152
    [No Abstract]   [Full Text] [Related]  

  • 17. Conquering hepatitis C, step by step.
    Schafer DF; Sorrell MF
    N Engl J Med; 2000 Dec; 343(23):1723-4. PubMed ID: 11106723
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C.
    Comai S; Cavalletto L; Chemello L; Bernardinello E; Ragazzi E; Costa CV; Bertazzo A
    Pharmacol Res; 2011 Jan; 63(1):85-92. PubMed ID: 20940053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C].
    Abellán Galiana P; Pérez-Lázaro A; Aguilera Sancho-Tello V; Merino Torres JF; Berenguer Haym M; Piñón Sellés F
    Endocrinol Nutr; 2009 Mar; 56(3):136-9. PubMed ID: 19627727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin.
    Neri S; Bertino G; Petralia A; Giancarlo C; Rizzotto A; Calvagno GS; Mauceri B; Abate G; Boemi P; Di Pino A; Ignaccolo L; Vadalà G; Misseri M; Maiorca D; Mastrosimone G; Judica A; Palermo F
    J Clin Gastroenterol; 2010 Oct; 44(9):e210-7. PubMed ID: 20838237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.